Report details status of device connectivity

The adoption of connected healthcare infrastructure is not uniform across the world, primarily due to the lack of a holistic digital healthcare strategy that focuses on integrated care models, according to analysis from Frost & Sullivan.

Healthcare and Medical Device Connectivity and Interoperability finds that "more than 50 percent of healthcare providers do not have a healthcare IT roadmap, although they acknowledge the role of digital health in enhancing healthcare efficiency," said Frost & Sullivan Healthcare Research Analyst Shruthi Parakkal. "Consequently, even the existing interoperability standards such as HL7, DICOM and Direct Project are not being utilized optimally by many providers."

Furthermore, hospitals are often required to update processes and workflows through expensive upgrades and reviews of codes and software. This process becomes more complicated in the absence of vendors that can guarantee connectivity between devices from various manufacturers.

"Hospitals/healthcare providers have an urgent requirement for connected devices and health IT solutions not only to manage healthcare data, but also to qualify Meaningful Use requirements and be eligible for electronic health record incentives," noted Parakkal. "Therefore, manufacturers of vendor-agnostic and open medical connectivity solutions are in demand, as they facilitate the integration of devices from different original equipment manufacturers."

Alliances that harness interoperability and enable information sharing between devices and health IT solutions from different vendors will go a long way in augmenting connectivity, according to Frost & Sullivan, while advances in WiFi, Bluetooth, and radio frequency identification also help further the cause.

Access the complete report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.